Reported positive preliminary topline data from global Phase 2 Seabreeze STAT studies evaluating rademikibart as an adjunct treatment for acute exacerbations of asthma and chronic obstructive pulmonary disease COPD Plans
Why Is Connect Biopharma Holdings Limited (CNTB) Stock Down Today?
Updated Nov 17, 2026 2:48 PM ET · Prev Close $0.64
Session Regime & Catalyst Assessment
68% Signal ConvictionConnect Biopharma Holdings Limited Pulling Back 7.94% on 1.28x Relative Volume
Connect Biopharma Holdings Limited (CNTB) is pulling back 7.94% (-$0.05) to $0.59 on 1.28x average session volume. Relative to benchmarks, CNTB is lagging the S&P 500 by -6.60%. 14-day RSI stands at 25.6, keeping momentum in a oversold regime.
Reported positive preliminary topline data from global Phase 2 Seabreeze STAT studies evaluating rademikibart as an adjunct treatment for acute exacerbations of asthma and chronic obstructive pulmonary disease COPD Plans
Price ($0.59) trades relative to 20-day SMA ($0.75) and 50-day SMA ($0.99).
Market & Sector Relative Strength
CNTB lagging the S&P 500 by -6.60%Options Flow & Execution Desk
Recent CNTB Catalyst Headlines
Verified WireConnect Biopharma Holdings is back in focus after analysts refreshed their price targets, with fair value moving from US 5.88 to US 6.00 in the latest models. The shift follows new Street research that weighs the mixed P
Connect Biopharma Holdings CNTB is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates coul
Connect Biopharma Holdings CNTB witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend
1–3 Day Expected Range & Key Level
54% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $0.55 (session support) for directional breakout confirmation.
Technical Regime (CNTB)
BEARISH MA TRENDRetail & Crowd Sentiment
Very BullishConnect Biopharma reported positive preliminary topline data from Phase 2 Seabreeze STAT studies for rademikibart as an adjunct treatment for acute exacerbations of asthma and COPD. The company plans to engage with the FDA to discuss potential Phase 3 programs.
About Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways …
Get Instant CNTB Catalyst Alerts
Receive an email alert when CNTB triggers an unusual volume breakout, options sweep, or rating shift.
Other Liquid Stocks Moving Today
All Today's MoversCNTB Session & Catalyst FAQ
Why is CNTB stock down today?
Connect Biopharma Holdings Limited (CNTB) is pulling back 7.94% (-$0.05) to $0.59 on 1.28x average session volume. Relative to benchmarks, CNTB is lagging the S&P 500 by -6.60%. 14-day RSI stands at 25.6, keeping momentum in a oversold regime.
Is CNTB stock a buy or sell right now?
Today's session carries a 68% catalyst conviction score on 1.28x relative volume (moderate participation). Our multi-factor model currently rates CNTB as HOLD. Review full valuation, quality, and timing signals on the CNTB Buy or Sell Decision Brief →
What is CNTB's intrinsic value and expected trading range?
At $0.59, CNTB's modeled 1-to-3 session range is $0.56 – $0.62, with a key inflection level at $0.55 (session support). Compare current price against multi-year cash flow projections in the CNTB Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
What do RSI and moving averages signal for CNTB?
RSI at 25.6 indicates oversold conditions — watch for mean-reversion support. CNTB trades at $0.59 relative to its 20-day SMA ($0.75) and 50-day SMA ($0.99), reflecting a bearish moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.